ORMP
Oramed
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
Significant Net Income Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ORMP
Oramed Pharmaceuticals Inc.
A developer of oral drug delivery systems
1185 Avenue of the Americas
, Third Floor
, New York
, NY 10036
Engaged in the research and development of innovative drug solutions.
Oramed Pharmaceuticals Inc., a Delaware corporation, was incorporated on April 12, 2002. The company is a pharmaceutical company engaged in the development of innovative pharmaceutical solutions, and its technology platform allows oral delivery of therapeutic proteins. The company has developed an oral dosage form designed to withstand the harsh environment of the stomach and effectively deliver active biological insulin or protein. The excipients in the formula are not designed for chemical or biological modification of proteins, and the dosage form is designed for safe ingestion.
Company Financials
EPS
ORMP has released its 2024 Q1 earnings. EPS was reported at 0.04, versus the expected 0.02, beating expectations. The chart below visualizes how ORMP has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ORMP has released its 2025 Q1 earnings report, with revenue of 2.00M, reflecting a YoY change of NaN%, and net profit of -7.64M, showing a YoY change of -598.17%. The Sankey diagram below clearly presents ORMP's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
